Skip to main content

Duchenne-focused biotech Sarepta loses billions in value after trial fail

Shares of Sarepta Therapeutics Inc., which employs more than 600 people in Massachusetts, were cut in half in after-hours trading Thursday night after the failure of a highly anticipated gene therapy for Duchenne muscular dystrophy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.